ZFIN ID: ZDB-FISH-150901-23930
Fish name: i114Tg
Genotype: i114Tg
Targeting Reagent: none
HUMAN DISEASE MODELED by i114Tg
Human Disease Conditions Citations
tuberculosis bacterial treatment by injection: Mycobacterium marinum E11 Carvalho et al., 2011
fungal infectious disease fungal treatment by injection: Mucor circinelloides Inglesfield et al., 2018
candidiasis fungal treatment by injection: Candida albicans Ho et al., 2019
gastrointestinal system disease chemical treatment by environment: dextran sulfate Oehlers et al., 2017
chemical treatment by environment: 2,4,5-trinitrobenzenesulfonic acid Oehlers et al., 2017
GENE EXPRESSION
Gene expression in i114Tg
RNA expression
Expressed Gene Structure Conditions Figures
apoa4b.1 control Fig. S3 from Rougeot et al., 2019
cd36 standard conditions Fig. 5 from Fink et al., 2015
cxcl8a chemical treatment by environment: double-stranded DNA Fig. 1 from de Oliveira et al., 2015
transection: caudal fin Fig. 1 from de Oliveira et al., 2015
Fig. 4 from Ogryzko et al., 2014
cxcl8b.1 chemical treatment by environment: double-stranded DNA Fig. 1 from de Oliveira et al., 2015
viral treatment by exposure to environment: Carp sprivivirus Fig. 1 from de Oliveira et al., 2015
defbl1 control Fig. 3 with image from Galindo-Villegas et al., 2012
germ free Fig. 3 with image from Galindo-Villegas et al., 2012
gbp4 control Fig. 1 from Tyrkalska et al., 2016
bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium Fig. 1 from Tyrkalska et al., 2016
grna control Fig. S3 from Rougeot et al., 2019
grna.1 control Fig. S3 from Rougeot et al., 2019
grna.2 control Fig. S3 from Rougeot et al., 2019
il1b control Fig. 1 from Tyrkalska et al., 2016
Fig. 3 with image from Galindo-Villegas et al., 2012
germ free Fig. 1 from Tyrkalska et al., 2016
Fig. 1 with imageFig. 4 from Ogryzko et al., 2014
Fig. 3 with image from Galindo-Villegas et al., 2012
irf4a standard conditions Fig. 1 with image from Wang et al., 2015
lcp1 standard conditions Fig. 1 from Renshaw et al., 2006
lyz standard conditions Fig. 1 with image from Wang et al., 2015
marco control Fig. S3 from Rougeot et al., 2019
mmp9 control Fig. S3 from Rougeot et al., 2019
mpeg1.1 standard conditions Fig. 1 from Benard et al., 2015
mpeg1.2 standard conditions Fig. S3 from Rougeot et al., 2019
Fig. 1 from Benard et al., 2015
mpx standard conditions Fig. S3 from Rougeot et al., 2019
Fig. 5 from Fink et al., 2015
Fig. 1 from Renshaw et al., 2006
nfil3 standard conditions Fig. 1 from Progatzky et al., 2012
npsn control Fig. 1 with image from Di et al., 2017
ptgs2b transection: caudal fin Fig. 4 from Ogryzko et al., 2014
caiap bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium Fig. 3 from Tyrkalska et al., 2017
spi1a control Fig. S3 from Rougeot et al., 2019
tnfa standard conditions Fig. 7 from Espín-Palazón et al., 2014
Protein expression
Antibody Antigen Genes Structure Conditions Figures
Ab2-lcp1 physical alteration: anatomical structure Fig. 6 from Varela et al., 2014
Fig. 1 with image from Jones et al., 2013
Ab1-lcp1 control Fig. 4 from Kanwal et al., 2013
Ab1-nitrotyrosine chemical treatment: pharmaceutical Fig. 4 with image from Elks et al., 2014
Ab1-nitrotyrosine bacterial treatment Fig. 1 with imageFig. 2 with imageFig. 3 with imageFig. 4 with imageFig. 5 with image from Elks et al., 2014
Fig. 3 with imageFig. 7 from Elks et al., 2013
Ab1-gnb control Fig. 2 with image from Ke et al., 2017
Ab1-nitrotyrosine standard conditions Fig. 1 with imageFig. 2 with imageFig. 3 with imageFig. 4 with imageFig. 5 with image from Elks et al., 2014
Fig. 3 with imageFig. 7 from Elks et al., 2013
Ab-2F11 control Fig. 3 from Lorent et al., 2015
Ab2-nos standard conditions Fig. 1 with image from Elks et al., 2014
Fig. 5 with image from Elks et al., 2013
Ab2-nos bacterial treatment Fig. 1 with image from Elks et al., 2014
Ab2-lcp1 standard conditions Fig. 6 from Varela et al., 2014
Fig. S1 with image from Jones et al., 2013
Ab-2F11 chemical treatment: biliatresone Fig. 3 from Lorent et al., 2015
Ab1-gnb1a control Fig. 2 with image from Ke et al., 2017
Ab4-GFP GFP control Fig. 2 with image from Hedrera et al., 2013
PHENOTYPE
Phenotype in i114Tg
Phenotype Conditions Figures
acute inflammatory response increased occurrence, abnormal chemical treatment: copper(II) sulfate Fig. 3 with image from Gallardo et al., 2015
caudal fin neutrophil amount, ameliorated transection: caudal fin, chemical treatment by environment: AH23848, chemical treatment by environment: prostaglandin E2 Fig. 4 with image from Loynes et al., 2018
caudal fin neutrophil decreased amount, abnormal transection: caudal fin, chemical treatment by environment: prostaglandin E2 Fig. 3 with image from Loynes et al., 2018
caudal fin neutrophil decreased amount, abnormal transection: caudal fin, chemical treatment by injection: lipoxin A4 Fig. 6 from Loynes et al., 2018
caudal fin neutrophil increased amount, abnormal transection: caudal fin, chemical treatment by injection: EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor Fig. 5 from Loynes et al., 2018
caudal fin neutrophil increased amount, abnormal transection: caudal fin, chemical treatment by injection: EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor, chemical treatment by environment: prostaglandin E2 Fig. 5 from Loynes et al., 2018
caudal fin neutrophil increased amount, abnormal transection: caudal fin, chemical treatment by environment: AH23848 Fig. 4 with image from Loynes et al., 2018
caudal fin regenerating fin decreased accumulation neutrophil, abnormal transection: caudal fin, chemical treatment: tyrphostin AG 825 Figure 6 with image from Rahman et al., 2019
caudal fin regenerating fin decreased accumulation neutrophil, abnormal transection: caudal fin, chemical treatment: CP-724714 Figure 6 with image from Rahman et al., 2019
caudal hematopoietic tissue neoplasm increased amount, abnormal cancer xenotransplantation Fig. 3 with image from Kiener et al., 2019
caudal hematopoietic tissue neutrophil apoptotic process increased occurrence, abnormal chemical treatment: tyrphostin AG 825 Figure 6 with image from Rahman et al., 2019
caudal hematopoietic tissue neutrophil apoptotic process occurrence, normal chemical treatment: CP-724714 Figure 6 with image from Rahman et al., 2019
cysteine-type endopeptidase activity involved in apoptotic process decreased occurrence, abnormal chemical treatment by environment: EC 3.4.22.36 (caspase-1) inhibitor Fig. 1Fig. 4 from Tyrkalska et al., 2019
cysteine-type endopeptidase activity involved in apoptotic process decreased occurrence, abnormal chemical treatment by environment: EC 3.4.22.36 (caspase-1) inhibitor, bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium Fig. 4 from Tyrkalska et al., 2019
cysteine-type endopeptidase activity involved in apoptotic process increased occurrence, abnormal bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium Fig. 4 from Tyrkalska et al., 2019
gall bladder morphology, abnormal chemical treatment: biliatresone Fig. 3 from Lorent et al., 2015
gill neutrophil amount, ameliorated chemical treatment: environmental contaminant Fig. 4 from Progatzky et al., 2016
gill neutrophil decreased amount, abnormal chemical treatment: environmental contaminant Fig. 3Fig. 4 from Progatzky et al., 2016
heart leukocyte activation increased occurrence, abnormal chemical treatment by environment: isoprenaline Fig. 6 from Kossack et al., 2017
heart neutrophil increased amount, abnormal chemical treatment by environment: isoprenaline Fig. 6 from Kossack et al., 2017
hindbrain macrophage decreased amount, abnormal fungal treatment by injection: Mucor circinelloides, chemical treatment by environment: dexamethasone Fig. 2 from Inglesfield et al., 2018
hindbrain neutrophil decreased amount, abnormal fungal treatment by injection: Mucor circinelloides, chemical treatment by environment: dexamethasone Fig. 2 from Inglesfield et al., 2018
hindbrain neutrophil increased amount, abnormal fungal treatment by injection: Mucor circinelloides Fig. 2 with image from Voelz et al., 2015
inflammatory response to wounding process quality, abnormal transection: caudal fin, chemical treatment: CP-724714 Figure 6 with image from Rahman et al., 2019
inflammatory response to wounding process quality, abnormal transection: caudal fin, chemical treatment: tyrphostin AG 825 Figure 6 with image from Rahman et al., 2019
intestine anatomical region has extra parts of type neutrophil, abnormal bacterial treatment by diet: Escherichia coli O157:H7 Fig. 3 with image from Stones et al., 2017
intestine neutrophil amount, ameliorated chemical treatment by diet: glycoprotein, protein content Fig. 1 with image from Ulloa et al., 2016
intestine neutrophil amount, ameliorated chemical treatment by environment: cabergoline, chemical treatment by environment: dextran sulfate Fig. 2 from Oehlers et al., 2017
intestine neutrophil amount, ameliorated chemical treatment by environment: 2,4,5-trinitrobenzenesulfonic acid, chemical treatment by environment: cabergoline Fig. 2 from Oehlers et al., 2017
intestine neutrophil amount, ameliorated chemical treatment by environment: 2,4,5-trinitrobenzenesulfonic acid, chemical treatment by environment: sincalide Fig. 3 from Oehlers et al., 2017
intestine neutrophil decreased amount, abnormal germ free Fig. 1 with image from Koch et al., 2018
intestine neutrophil increased amount, abnormal chemical treatment by environment: dextran sulfate, chemical treatment by environment: sincalide Fig. 3 from Oehlers et al., 2017
intestine neutrophil increased amount, abnormal chemical treatment by environment: dextran sulfate Fig. 2Fig. 3 from Oehlers et al., 2017
intestine neutrophil increased amount, abnormal chemical treatment by environment: 2,4,5-trinitrobenzenesulfonic acid Fig. 1Fig. 2Fig. 3 from Oehlers et al., 2017
intestine neutrophil increased amount, abnormal chemical treatment by diet: glycoprotein, protein content Fig. 1 with image from Ulloa et al., 2016
intestine neutrophil increased amount, exacerbated chemical treatment by environment: haloperidol, chemical treatment by environment: dextran sulfate Fig. 2 from Oehlers et al., 2017
intestine neutrophil increased amount, exacerbated chemical treatment by environment: lorglumide Fig. 3 from Oehlers et al., 2017
intestine neutrophil increased amount, exacerbated chemical treatment by environment: dextran sulfate, chemical treatment by environment: devazepide Fig. 3 from Oehlers et al., 2017
intestine neutrophil increased amount, exacerbated chemical treatment by environment: devazepide, chemical treatment by environment: 2,4,5-trinitrobenzenesulfonic acid Fig. 3 from Oehlers et al., 2017
intestine neutrophil increased amount, exacerbated chemical treatment by environment: lorglumide, chemical treatment by environment: dextran sulfate, chemical treatment by environment: 2,4,5-trinitrobenzenesulfonic acid Fig. 3 from Oehlers et al., 2017
intestine neutrophil infiltrative, abnormal chemical treatment by injection: 4-(ethoxymethylene)-2-phenyloxazol-5-one Fig. 4 from Brugman et al., 2009
leukocyte il1b expression amount, ameliorated transection: caudal fin, chemical treatment by environment: purinergic receptor P2X antagonist Fig. 4 from Ogryzko et al., 2014
leukocyte il1b expression amount, ameliorated transection: caudal fin, chemical treatment by environment: EC 3.4.22.36 (caspase-1) inhibitor Fig. 4 from Ogryzko et al., 2014
leukocyte il1b expression increased amount, abnormal transection: caudal fin Fig. 4 from Ogryzko et al., 2014
leukocyte cxcl8a expression increased amount, abnormal transection: caudal fin Fig. 4 from Ogryzko et al., 2014
leukocyte ptgs2b expression increased amount, abnormal transection: caudal fin, chemical treatment by environment: purinergic receptor P2X antagonist Fig. 4 from Ogryzko et al., 2014
leukocyte ptgs2b expression increased amount, abnormal transection: caudal fin, chemical treatment by environment: EC 3.4.22.36 (caspase-1) inhibitor Fig. 4 from Ogryzko et al., 2014
leukocyte ptgs2b expression increased amount, abnormal transection: caudal fin Fig. 4 from Ogryzko et al., 2014
leukocyte cxcl8a expression increased amount, abnormal transection: caudal fin, chemical treatment by environment: EC 3.4.22.36 (caspase-1) inhibitor Fig. 4 from Ogryzko et al., 2014
leukocyte cxcl8a expression increased amount, abnormal transection: caudal fin, chemical treatment by environment: purinergic receptor P2X antagonist Fig. 4 from Ogryzko et al., 2014
leukocyte protein nitrosylation increased process quality, abnormal bacterial treatment Fig. 3 with imageFig. 7 from Elks et al., 2013
leukocyte migration involved in inflammatory response process quality, abnormal physical alteration: anatomical structure, chemical treatment: pharmaceutical Fig. 3Fig. 5Fig. 6 from Burgon et al., 2014
leukocyte migration involved in inflammatory response process quality, abnormal physical alteration: anatomical structure, chemical treatment: pharmaceutical Fig. 6 from Burgon et al., 2014
leukocyte migration involved in inflammatory response process quality, abnormal physical alteration: caudal fin, chemical treatment: pharmaceutical Fig. 7 from de Oliveira et al., 2013
macrophage accumulation caudal fin, abnormal chemical treatment by environment: lipopolysaccharide Fig. 4 from Philip et al., 2017
macrophage accumulation liver and biliary system, abnormal chemical treatment: biliatresone Fig. 3 from Lorent et al., 2015
macrophage decreased amount, abnormal viral treatment: Carp sprivivirus Fig. 6 from Varela et al., 2014
neutrophil accumulation swim bladder, abnormal fungal treatment by injection: Mucor circinelloides Fig. 5 with image from Voelz et al., 2015
neutrophil accumulation liver and biliary system, abnormal chemical treatment: biliatresone Fig. 3 from Lorent et al., 2015
neutrophil amount, normal bacterial treatment by exposure to environment: Pseudomonas aeruginosa Fig. 1 with image from Díaz-Pascual et al., 2017
neutrophil decreased amount, abnormal chemical treatment by environment: EC 3.4.22.36 (caspase-1) inhibitor, bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium Fig. 4 from Tyrkalska et al., 2019
neutrophil decreased amount, abnormal chemical treatment by environment: EC 3.4.22.36 (caspase-1) inhibitor Fig. 1Fig. 4 from Tyrkalska et al., 2019
neutrophil decreased amount, abnormal bacterial treatment by injection: Burkholderia cenocepacia Fig. 3 with image from Mesureur et al., 2017
neutrophil decreased amount, abnormal chemical treatment by environment: sunitinib Fig. 3 from Delasoie et al., 2020
neutrophil decreased amount, abnormal chemical treatment by environment: doxorubicin Fig. 3 from Delasoie et al., 2020
neutrophil decreased speed, abnormal physical alteration: anatomical structure, chemical treatment: pharmaceutical Fig. 6 from Burgon et al., 2014
neutrophil decreased speed, abnormal physical alteration: anatomical structure, chemical treatment: pharmaceutical Fig. 4Fig. 6 from Burgon et al., 2014
neutrophil increased amount, abnormal chemical treatment by injection: 4-(ethoxymethylene)-2-phenyloxazol-5-one Fig. 4 from Brugman et al., 2009
neutrophil caiap expression increased amount, abnormal bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium Fig. 3 from Tyrkalska et al., 2017
neutrophil increased amount, abnormal bacterial treatment by injection: Escherichia coli DH5[alpha] Fig. 3 with image from Díaz-Pascual et al., 2017
neutrophil increased amount, abnormal bacterial treatment by injection: Pseudomonas aeruginosa Fig. 3 with image from Díaz-Pascual et al., 2017
neutrophil increased amount, abnormal bacterial treatment by injection: Burkholderia stabilis Fig. 3 with image from Mesureur et al., 2017
neutrophil increased amount, abnormal fungal treatment by injection: Mucor circinelloides Fig. 1 from Inglesfield et al., 2018
neutrophil il1b expression increased amount, abnormal bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium Fig. 1 from Tyrkalska et al., 2016
neutrophil increased amount, abnormal chemical treatment by environment: 2,4,5-trinitrobenzenesulfonic acid Fig. 1 from Oehlers et al., 2017
neutrophil increased amount, abnormal bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium Fig. 4 from Tyrkalska et al., 2019
neutrophil increased amount, abnormal bacterial treatment by injection: Burkholderia cenocepacia Fig. 7 with image from Mesureur et al., 2017
neutrophil mislocalised, abnormal standard conditions Fig. Sup. 1 from Lu et al., 2020
neutrophil normal amount, normal chemical treatment: pharmaceutical Fig. 3 with image from Herbst et al., 2015
neutrophil shape, abnormal standard conditions Fig. Sup. 1 from Lu et al., 2020
neutrophil apoptotic process increased process quality, abnormal physical alteration: anatomical structure, chemical treatment: pharmaceutical Fig. 3 from Burgon et al., 2014
neutrophil inflammatory response to wounding decreased duration, abnormal transection: caudal fin, chemical treatment by environment: prostaglandin E2 Fig. 3 with image from Loynes et al., 2018
neutrophil inflammatory response to wounding decreased duration, abnormal transection: caudal fin, chemical treatment by injection: lipoxin A4 Fig. 6 from Loynes et al., 2018
neutrophil inflammatory response to wounding increased duration, abnormal transection: caudal fin, chemical treatment by injection: EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor Fig. 5 from Loynes et al., 2018
neutrophil inflammatory response to wounding increased duration, abnormal transection: caudal fin, chemical treatment by injection: EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor, chemical treatment by environment: prostaglandin E2 Fig. 5 from Loynes et al., 2018
neutrophil apoptotic process increased occurrence, abnormal transection: caudal fin, chemical treatment by injection: 4-(2,6-dichlorobenzamido)-N-(piperidin-4-yl)-pyrazole-3-carboxamide Fig. 3 with image from Hoodless et al., 2016
neutrophil apoptotic process occurrence, normal transection: caudal fin, chemical treatment by injection: 4-(2,6-dichlorobenzamido)-N-(piperidin-4-yl)-pyrazole-3-carboxamide Fig. 3 with image from Hoodless et al., 2016
neutrophil chemotaxis decreased occurrence, abnormal chemical treatment by environment: SB220025, amputation: caudal fin Fig. 4 from de Oliveira et al., 2015
neutrophil chemotaxis decreased occurrence, abnormal chemical treatment by environment: anthra[1,9-cd]pyrazol-6(2H)-one, amputation: caudal fin Fig. 4 from de Oliveira et al., 2015
neutrophil chemotaxis decreased occurrence, abnormal chemical treatment by environment: 2-(2-amino-3-methoxyphenyl)chromen-4-one, amputation: caudal fin Fig. 4 from de Oliveira et al., 2015
neutrophil chemotaxis decreased occurrence, abnormal chemical treatment by environment: wortmannin, amputation: caudal fin Fig. 4 from de Oliveira et al., 2015
neutrophil chemotaxis decreased occurrence, abnormal chemical treatment by environment: PP2, amputation: caudal fin Fig. 4 from de Oliveira et al., 2015
neutrophil chemotaxis decreased occurrence, abnormal transection: caudal fin, chemical treatment by environment: purinergic receptor P2X antagonist Fig. 2 from Ogryzko et al., 2014
neutrophil chemotaxis decreased occurrence, abnormal transection: caudal fin, chemical treatment by environment: EC 3.4.22.36 (caspase-1) inhibitor Fig. 2 from Ogryzko et al., 2014
neutrophil chemotaxis decreased occurrence, abnormal chemical treatment by environment: inhibitor, amputation: caudal fin Fig. 1 with image from Ke et al., 2017
neutrophil chemotaxis decreased process quality, abnormal amputation: caudal fin, chemical treatment: dibenziodolium chloride Fig. 2 from de Oliveira et al., 2014
neutrophil chemotaxis decreased process quality, abnormal chemical treatment by environment: inhibitor, amputation: caudal fin Fig. 1 with image from Ke et al., 2017
neutrophil chemotaxis increased occurrence, abnormal bacterial treatment by diet: Escherichia coli O157:H7 Fig. 3 with image from Stones et al., 2017
neutrophil chemotaxis increased occurrence, abnormal bacterial treatment by injection: Pseudomonas aeruginosa Fig. 3 with image from Díaz-Pascual et al., 2017
neutrophil chemotaxis increased occurrence, abnormal bacterial treatment by injection: Escherichia coli DH5[alpha] Fig. 3 with image from Díaz-Pascual et al., 2017
neutrophil migration decreased occurrence, abnormal chemical treatment by environment: inhibitor, amputation: caudal fin Fig. 1 with image from Ke et al., 2017
neutrophil migration decreased process quality, abnormal chemical treatment by environment: inhibitor, amputation: caudal fin Fig. 1 with image from Ke et al., 2017
neutrophil migration decreased process quality, abnormal transection: caudal fin, chemical treatment by environment: isopimpinellin Fig. 2 with image from Robertson et al., 2016
neutrophil migration process quality, abnormal chemical treatment by environment: inhibitor, amputation: caudal fin Fig. 1 with image from Ke et al., 2017
neutrophil migration process quality, abnormal physical alteration: anatomical structure, chemical treatment: pharmaceutical Fig. 6 from Burgon et al., 2014
neutrophil migration process quality, abnormal physical alteration: anatomical structure, chemical treatment: pharmaceutical Fig. 3Fig. 4Fig. 5Fig. 6 from Burgon et al., 2014
neutrophil migration process quality, normal bacterial treatment by exposure to environment: Pseudomonas aeruginosa Fig. 1 with image from Díaz-Pascual et al., 2017
neutrophil-mediated killing of fungus process quality, normal fungal treatment by injection: Candida albicans Fig. 2 from Brothers et al., 2011
notochord neutrophil increased amount, abnormal bacterial treatment by injection: Escherichia coli K-12 Fig. 7 with image from Nguyen-Chi et al., 2014
phagocytosis process quality, normal fungal treatment by injection: Candida albicans Fig. 2 from Brothers et al., 2011
regenerating fin neutrophil decreased amount, abnormal transection: caudal fin, chemical treatment by injection: 4-(2,6-dichlorobenzamido)-N-(piperidin-4-yl)-pyrazole-3-carboxamide Fig. 2 with imageFig. 7 with image from Hoodless et al., 2016
regenerating fin neutrophil decreased amount, abnormal transection: caudal fin, chemical treatment by environment: alvocidib Fig. 2 with image from Hoodless et al., 2016
regenerating fin neutrophil apoptotic process increased occurrence, abnormal transection: caudal fin, chemical treatment: tyrphostin AG 825 Figure 6 with image from Rahman et al., 2019
regenerating fin neutrophil apoptotic process increased occurrence, abnormal transection: caudal fin, chemical treatment: CP-724714 Figure 6 with image from Rahman et al., 2019
regenerating fin neutrophil chemotaxis occurrence, normal transection: caudal fin, chemical treatment by injection: 4-(2,6-dichlorobenzamido)-N-(piperidin-4-yl)-pyrazole-3-carboxamide Fig. 2 with image from Hoodless et al., 2016
regenerating fin neutrophil chemotaxis occurrence, normal transection: caudal fin, chemical treatment by environment: alvocidib Fig. 2 with image from Hoodless et al., 2016
regeneration epithelium neutrophil decreased amount, abnormal transection: caudal fin Fig. 6 with image from Robertson et al., 2016
regeneration epithelium neutrophil decreased amount, abnormal transection: caudal fin, chemical treatment by injection: nedocromil Fig. 6 with image from Robertson et al., 2016
regeneration epithelium neutrophil decreased amount, abnormal transection: caudal fin, chemical treatment by environment: isopimpinellin Fig. 2 with imageFig. 3 with image from Robertson et al., 2016
skeletal muscle neutrophil increased amount, abnormal viral treatment by injection: unidentified influenza virus Fig. 4 with image from Goody et al., 2017
skeletal muscle cell degenerate, abnormal viral treatment by injection: unidentified influenza virus Fig. 4 with image from Goody et al., 2017
skeletal muscle cell detached from skeletal muscle cell, abnormal viral treatment by injection: unidentified influenza virus Fig. 4 with image from Goody et al., 2017
swim bladder neutrophil decreased amount, abnormal chemical treatment by environment: epidermal growth factor receptor antagonist, fungal treatment by injection: Candida albicans Fig. 3 with image from Ho et al., 2019
trunk neutrophil increased amount, abnormal chemical treatment by environment: 2,4,5-trinitrobenzenesulfonic acid Fig. 1 from Oehlers et al., 2017
ventral fin fold neutrophil localized, abnormal transection: ventral fin fold Fig. 3 with image from Coombs et al., 2019
ventral fin fold neutrophil migration increased occurrence, abnormal transection: ventral fin fold Fig. 3 with image from Coombs et al., 2019
whole organism decreased life span, abnormal chemical treatment by environment: epidermal growth factor receptor antagonist, fungal treatment by injection: Candida albicans Fig. 3 with image from Ho et al., 2019
whole organism decreased life span, abnormal fungal treatment by injection: Mucor circinelloides, chemical treatment by environment: dexamethasone Fig. 2 from Inglesfield et al., 2018
whole organism gbp4 expression increased amount, abnormal bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium Fig. 1 from Tyrkalska et al., 2016
whole organism cxcl8b.1 expression increased amount, abnormal chemical treatment by environment: double-stranded DNA Fig. 1 from de Oliveira et al., 2015
whole organism cxcl8b.1 expression increased amount, abnormal chemical treatment by environment: poly(I:C) Fig. 1 from de Oliveira et al., 2015
whole organism cxcl8b.1 expression increased amount, abnormal bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium Fig. 1 from de Oliveira et al., 2015
whole organism cxcl8b.1 expression increased amount, abnormal viral treatment by exposure to environment: Carp sprivivirus Fig. 1 from de Oliveira et al., 2015
whole organism cxcl8a expression increased amount, abnormal chemical treatment by environment: poly(I:C) Fig. 1 from de Oliveira et al., 2015
whole organism cxcl8a expression increased amount, abnormal chemical treatment by environment: double-stranded DNA Fig. 1 from de Oliveira et al., 2015
whole organism cxcl8a expression increased amount, abnormal viral treatment by exposure to environment: Carp sprivivirus Fig. 1 from de Oliveira et al., 2015
whole organism cxcl8a expression increased amount, abnormal bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium Fig. 1 from de Oliveira et al., 2015
whole organism il1b expression increased amount, abnormal bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium Fig. 1 from Tyrkalska et al., 2016
whole organism neutrophil amount, normal chemical treatment: tyrphostin AG 825 Figure 6 with image from Rahman et al., 2019
whole organism neutrophil amount, normal chemical treatment: CP-724714 Figure 6 with image from Rahman et al., 2019
whole organism neutrophil amount, normal transection: caudal fin, chemical treatment by environment: alvocidib Fig. 2 with image from Hoodless et al., 2016
whole organism neutrophil amount, normal transection: caudal fin, chemical treatment by injection: 4-(2,6-dichlorobenzamido)-N-(piperidin-4-yl)-pyrazole-3-carboxamide Fig. 2 with image from Hoodless et al., 2016
whole organism neutrophil normal amount, normal high fat Fig. 8 with image from Misselbeck et al., 2019
whole organism neutrophil normal amount, normal high cholesterol Fig. 8 with image from Misselbeck et al., 2019

CITATIONS  (141)